Volasertib for AML: clinical use and patient consideration
Zhonglin Hao,1 Vamsi Kota2 1Cancer Center, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA; 2Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA Abstract: Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients >65 years of...
Main Authors: | Hao Z, Kota V |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/volasertib-for-aml-clinical-use-and-patient-consideration-peer-reviewed-article-OTT |
Similar Items
-
Inhibition of Suicidal Erythrocyte Death by Volasertib
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2017-10-01) -
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
by: Hartmut Döhner, et al.
Published: (2021-08-01) -
Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression
by: Mi-Yeon Jeon, et al.
Published: (2017-11-01) -
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
by: Philip T. Sobash, et al.
Published: (2020-01-01) -
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
by: Lifeng Li, et al.
Published: (2020-09-01)